Oppenheimer & CO Inc Akebia Therapeutics, Inc. Transaction History

Oppenheimer & CO Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 31, 2019	SELL	$3.55 - $5.4 $42,955 - $65,340	-12,100 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$4.1 - $8.05 $4,346 - $8,533	-1,060 Reduced 8.05%	12,100 $59,000
Q1 2019 Apr 24, 2019	BUY	$5.41 - $8.73 $5,058 - $8,162	935 Added 7.65%	13,160 $108,000
Q4 2018 Jan 29, 2019	BUY	$5.39 - $9.15 $65,892 - $111,858	12,225 New	12,225 $68,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $338M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.